Bayer AG (BAYGn.DE)
84.65EUR
20 May 2013
€0.53 (+0.63%)
€83.79
€84.58
€85.30
€83.89
1,087,157
2,327,644
€85.67
€47.62
BAYGn.DE
About
Overall
| Beta: | 0.78 |
| Market Cap (Mil.): | €69,562.85 |
| Shares Outstanding (Mil.): | 826.95 |
| Dividend: | 1.90 |
| Yield (%): | 2.26 |
Financials
| BAYGn.DE | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 27.22 | 35.67 | 35.85 |
| EPS (TTM): | 3.09 | -- | -- |
| ROI: | 6.59 | 19.40 | 18.76 |
| ROE: | 12.89 | 20.11 | 19.57 |
German stocks - Factors to watch on May 21
FRANKFURT, May 21 - The DAX top-30 index looked set to open 0.2 percent lower on Tuesday, according to premarket data from brokerage Lang & Schwarz at 0620 GMT.
Bayer says lung drug shows promise in prolonged trial
FRANKFURT - Bayer said extended use of its experimental riociguat pill to treat a life-threatening form of high blood pressure in the lungs was shown to be safe and effective in a prolonged trial.
Bayer to acquire herbal medicine maker Steigerwald
FRANKFURT, May 16 - Germany's largest drugmaker Bayer said it agreed to buy privately held Steigerwald Arzneimittelwerk GmbH, a maker of herbal treatments.
Bayer, Algeta win FDA approval for prostate cancer drug
FRANKFURT, May 15 - German drugmaker Bayer and its development partner Algeta won approval from U.S. regulators for a prostate cancer drug that could eventually generate more than 1 billion euros ($1.31 billion) in annual sales.
Bayer's plastics chief sees room to raise prices
LEVERKUSEN, Germany - Bayer suggested there was room to lift prices at its high-tech plastics and chemicals business this year to counter soaring raw material costs that squeezed first quarter margins.
Court tells Bayer to compensate Schering shareholders
FRANKFURT, May 6 - A court ruled that Bayer did not pay some former Schering shareholders enough to acquire its German rival in 2007 and must now pay them more than 300 million euros ($392 million) in compensation, lawyers for the shareholders said.
Bayer stops drug trial with haemophilia drug BAY 86-6150
FRANKFURT, May 3 - Bayer said its HealthCare division stopped a Phase II/III study testing its experimental treatment BAY 86-6150 on certain haemophilia A and B patients due to safety concerns.
Bayer to buy birth-control devices maker for $1.1 billion
FRANKFURT - Germany's Bayer AG has agreed to buy U.S. contraceptive devices maker Conceptus for $1.1 billion, aiming to underpin its position as the world's largest women's healthcare provider,
UPDATE 1-Bayer to buy birth-control devices maker for $1.1 bln
* Purchase of Concetpus is latest in string of bolt-on deals
Earnings vs. 
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Finlabo SIM Spa
|
$58.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: ValuEngine, Inc.
|
$127.00
|
|
Provider: Wright Reports
|
$472.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
